BMRN - BioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings Call Transcript
2024-04-24 20:50:24 ET
BioMarin Pharmaceutical, Inc. (BMRN)
Q1 2024 Earnings Conference Call
April 24, 2024 04:30 PM ET
Company Participants
Traci McCarty - Head of IR
Alexander Hardy - President & CEO
Henry Fuchs - President, Worldwide Research & Development
Brian Mueller - EVP & CFO
Jeffrey Ajer - EVP & Chief Commercial Officer
Conference Call Participants
Phil Nadeau - TD Cowen
Geoff Meacham - Bank of America
Salveen Richter - Goldman Sachs
Christopher Raymond - Piper Sandler
Akash Tewari - Jefferies
Jessica Fye - JPMorgan
Joseph Schwartz - Leerink Partners
Gena Wang - Barclays
Ellie Merle - UBS Financial
Paul Matteis - Stifel
Mohit Bansal - Wells Fargo
Vikram Purohit - Morgan Stanley
Lachlan Hanbury-Brown - William Blair
Presentation
Operator
Good afternoon. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceutical First Quarter 2024 Conference Call. Today's conference is being recorded. All lines have been on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]
At this time, I'd like to turn the conference over to Traci McCarty, Group Vice President, Investor Relations. Please go ahead.
Traci McCarty
To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.
Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.
In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for or superior to financial measures prepared in accordance with U.S. GAAP, and you can find the related reconciliations to U.S. GAAP in the earnings release and earnings presentation, both of which are available in the Investor Relations section of our website.
On the call from BioMarin management today are Alexander Hardy, President and Chief Executive Officer; Hank Fuchs, President of Worldwide R&D; and Bert Brian Mueller, Executive Vice President, Chief Financial Officer. Jeff Ajer, Executive Vice President, Chief Commercial Officer; and Greg Guyer, Executive Vice President, Chief Technical Officer, are here with us to answer questions during the Q&A portion of the call....
BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript